Literature DB >> 29729163

Kallistatin level in patients with combination of chronic pancreatitis and aterosclerosis.

Elizaveta S Sirchak1, Svetlana M Opalenyk1, Natalia Yu Kurchak1.   

Abstract

OBJECTIVE: Introduction: The article is devoted to the optimization of complex diagnosis in patients with combination of chronic pancreatitis and atherosclerosis. The aim: To study the level of serum kallistatin in patients with combination of chronic pancreatitis and atherosclerosis. PATIENTS AND METHODS: Materials and methods: 89 patients with chronic pancreatitis were examined. The serum kallistatin level was determined by immunoassay using the Human Serpin A4 ELISA Kit from RayBiotech according to the application method. To determine the excretory pancreatic insufficiency all patients underwent 13C-amylase and 13C-mixed triglyceride breathing tests.
RESULTS:
Results: Analysis of the study results showed that patients with less severe excretory pancreatic insufficiency and lipid profile disorders had higher kallistatin level than the control group (33.66±4.55 ng/ml). Instead, in patients with severe excretory pancreatic insufficiency and dyslipidemia, it was significantly lower - 14.69±9.21 ng/ml.
CONCLUSION: Conclusions: The interrelation between the severity of the chronic pancreatitis course with atherosclerosis and the serum kallistatin level was observed. It has been established that studies of serum kallistatin level can serve as a marker of the chronic pancreatitis` severity in combination with atherosclerosis.

Entities:  

Keywords:  atherosclerosis ; chronic pancreatitis ; kallistatin

Mesh:

Substances:

Year:  2018        PMID: 29729163

Source DB:  PubMed          Journal:  Wiad Lek        ISSN: 0043-5147


  1 in total

1.  Relationship between Serum Kallistatin and Afamin and Anthropometric Factors Associated with Obesity and of Being Overweight in Patients after Myocardial Infarction and without Myocardial Infarction.

Authors:  Grzegorz Józef Nowicki; Barbara Ślusarska; Maciej Polak; Katarzyna Naylor; Tomasz Kocki
Journal:  J Clin Med       Date:  2021-12-10       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.